Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 -5.05%77 PB Ratio is 2.08 as of Jul. 20, 2026, which is 24% below its 10-year median of 2.74. GuruFocus rates TPE:1795 with a GF Score™ of 77/100 and a GF Value™ of NT$456.47 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 926 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks worse than 53.56% on this metric.
Lotus Pharmaceutical Co Ltd stock PB Ratio (=2.08) is close to 5-year low of 2.02.
The historical rank and industry rank for Lotus Pharmaceutical Co's PB Ratio or its related term are showing as below:
TPE:1795'
s PB Ratio Range Over the Past 10 Years
Min: 1.36 Med: 2.74 Max: 6.39
Current: 2.08
During the past 13 years, Lotus Pharmaceutical Co's highest PB Ratio was 6.39. The lowest was 1.36. And the median was 2.74.
TPE:1795's PB Ratio is ranked worse than 53.56% of 926
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs TPE:1795: 2.08
During the past 12 months, Lotus Pharmaceutical Co's average Book Value Per Share Growth Rate was 13.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lotus Pharmaceutical Co was 64.50% per year. The lowest was -20.00% per year. And the median was 15.10% per year.
Back to Basics: PB Ratio
Lotus Pharmaceutical Co (TPE:1795) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lotus Pharmaceutical Co (TPE:1795) has a PB Ratio of 2.08 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lotus Pharmaceutical Co and its competitors. This is 24% below median its historical median of 2.74. Over the past decade, Lotus Pharmaceutical Co's PB Ratio has ranged from 1.36 to 6.39. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #496 out of 926 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Lotus Pharmaceutical Co's PB Ratio too high?
Lotus Pharmaceutical Co's current PB Ratio of 2.08 is 24% below median its 10-year median of 2.74. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 6.39. The Drug Manufacturers industry median PB Ratio is 1.91. Lotus Pharmaceutical Co's value of 2.08 is 8.9% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #496 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #496 out of 926 companies for PB Ratio. This places Lotus Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.91. Lotus Pharmaceutical Co's value of 2.08 is 8.9% above this benchmark. Historically, Lotus Pharmaceutical Co's own PB Ratio has ranged from 1.36 to 6.39 over the past decade. While the company's 10-year median is 2.74 vs. the industry median of 1.91, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current PB Ratio of 2.08 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current PB Ratio is 2.08, which is 24% below median its own 10-year median of 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$456.47, compared to a current price of NT$188.00 — trading 58.8% below its estimated fair value. The current PB Ratio is 2.08, which is 24% below median its 10-year median of 2.74 and 8.9% above the Drug Manufacturers industry median of 1.91. Lotus Pharmaceutical Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current PB Ratio is 2.08 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$188.00 is trading 58.8% below its estimated GF Value™ of NT$456.47.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
PB Ratio: 2.08 (24% below median its 10-year median of 2.74)
GF Value™: NT$456.47 vs. price of NT$188.00 (58.8% below fair value)
Industry Position: 8.9% above the Drug Manufacturers median (#496 of 926)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
77GF Score
Get the complete analysis for TPE:1795
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
